No Data
China Resources Double-Crane Pharmaceutical (600062.SH): The injection of Pethidine hydrochloride has passed the consistency evaluation of generics in terms of quality and efficacy.
On December 30, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced that the company received the "Notification of Approval for Supplementary Application of Pharmaceutical" (Notification No.: 2024B06197) issued by the National Medical Products Administration for the injectable pethidine solution (referred to as "the Pharmaceutical"). The injectable pethidine solution is suitable for various kinds of chronic major pain, such as cancer pain, traumatic pain, and postoperative pain, and can also be used for preoperative or pre-anesthesia administration as an auxiliary medication for surgical anesthesia.
China Resources Double-Crane Pharmaceutical Plans Up to 500-Million-Yuan Investment in Financial Products
China Resources Double-Crane Pharmaceutical (600062.SH): DC10190 capsule has received the drug clinical trial approval notice.
Gelonghui reported on December 26 that China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary Peking Double-Crane Run Technology Co., Ltd. received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the DC10190 capsules. The DC10190 capsules are intended for the treatment of patients with advanced or metastatic solid tumors and are a type 1 new drug that has not yet been marketed domestically or internationally.
CR Double-Crane Pharma Gets Europe's Suitability Certificate for Dienogest
China Resources Double-Crane Pharmaceutical (600062.SH): The subsidiary's Active Pharmaceutical Ingredient for Dienogest has received CEP certification.
Gelonghui, December 25丨China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. (hereinafter referred to as "Qinhuangdao Zizhu") has received the European Pharmacopoeia suitability certificate for the Active Pharmaceutical Ingredient of Dienogest (hereinafter referred to as "the Active Pharmaceutical Ingredient") issued by the European Directorate for the Quality of Medicines & Healthcare (hereinafter referred to as "EDQM").
China Resources Double-Crane Pharmaceutical (600062.SH): Passed GMP compliance inspection.
On December 17, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced it has received the "Pharmaceutical GMP Compliance Inspection Notification" issued by the Peking Municipal Pharmaceutical Supervision Administration. This is the first pharmaceutical GMP compliance inspection before the market launch of Sugengutong Sodium Injection, conducted on a newly constructed production line based on the existing factory. The investment in the new workshop production equipment and facilities amounts to 12.9496 million yuan (unaudited). The company passing this pharmaceutical GMP compliance inspection indicates that its product production quality management meets GMP requirements, which will be beneficial for the company to continue maintaining stable production.
Earnings Update: Here's Why Analysts Just Lifted Their China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Price Target To CN¥24.91
